Navigating the procurement of high-purity growth-hormone-releasing hormone (GHRH) analogs requires strict adherence to analytical quality standards and verified lot documentation. This guide details the biochemical specifications, preclinical mechanisms, and sourcing requirements for investigators seeking to execute a CJC-1295 order for laboratory research.
Navigating the procurement of high-purity growth-hormone-releasing hormone (GHRH) analogs requires strict adherence to analytical quality standards and verified lot documentation. This guide details the biochemical specifications, preclinical mechanisms, and sourcing requirements for investigators seeking to execute a CJC-1295 order for laboratory research.
Placing a CJC-1295 order for laboratory research requires sourcing high-purity, synthetically manufactured growth-hormone-releasing hormone (GHRH) analogs accompanied by lot-specific third-party HPLC and mass spectrometry validation. Researchers must verify chemical purity exceeds 98% and endotoxin levels remain below 5 EU/mg before initiating in vitro or animal bioassays.
When preparing to purchase research peptides for cellular or animal models, investigators must differentiate between consumer distribution channels and verified scientific vendors. Research-grade CJC-1295 is intended strictly for in vitro assays and preclinical laboratory protocols. Procuring from suppliers that provide full batch traceability and transparent testing protocols ensures that experimental outcomes are not confounded by unlisted salts, residual counter-ions, or peptide degradation products. You can explore our complete inventory of catalog compounds via the all peptides directory.
CJC-1295 is a synthetic 30-amino acid peptide analog of endogenous growth-hormone-releasing hormone (GHRH). It functions as a GHRH receptor agonist, binding selectively to the GHRH receptor located on pituitary somatotropes. Upon receptor engagement, it activates the intracellular adenylate cyclase pathway, leading to an increase in cyclic adenosine monophosphate (cAMP) and subsequent release of endogenous growth hormone (GH).
Preclinical studies suggest that GHRH analogs play a key role in modulating downstream physiological processes, including hepatic insulin-like growth factor 1 (IGF-1) synthesis. In vitro assays demonstrate that sustained activation of the GHRH receptor maintains somatotrope responsiveness without causing rapid receptor desensitization, making CJC-1295 a critical tool for investigating endocrine signalling cascades. For broader background on somatotrophic research, visit our research literature repository.
When planning a CJC-1295 order, researchers must select between two distinct molecular variants: CJC-1295 with Drug Affinity Complex (DAC) and CJC-1295 without DAC (commonly referred to as Modified GRF 1-29). The primary structural distinction lies in the addition of a maleimidopropionic acid reactive group at the C-terminus of the DAC variant.
The DAC moiety enables covalent binding to endogenous serum albumin following administration in animal models, extending the plasma half-life of the compound from approximately 30 minutes to over 6 to 8 days. Conversely, CJC-1295 No DAC exhibits a significantly shorter half-life, mirroring a rapid, pulsatile release profile of growth hormone. Depending on whether your protocol requires sustained systemic elevation or transient stimulation, you can select the appropriate product page for CJC-1295 DAC or consult our deep-dive analysis on CJC-1295 DAC vs No DAC.
In vivo animal models have provided extensive data regarding the pharmacokinetic and pharmacodynamic parameters of CJC-1295. Rodent and non-human primate studies demonstrate that a single administration of CJC-1295 DAC results in dose-dependent increases in plasma GH levels lasting up to 7 days, alongside a 2- to 4-fold elevation in circulating IGF-1 concentrations sustained for up to 14 days.
Importantly, preclinical data indicate that despite prolonged receptor exposure, the normal physiological feedback loops governing GH release remain intact. In vitro studies using isolated pituitary cells confirm that the peptide stimulates GH secretion while permitting endogenous somatostatin to exert inhibitory control during natural baseline phases. This unique profile permits researchers to evaluate long-term endocrine stimulation without inducing complete pituitary suppression.
CJC-1295 is widely utilized in studies evaluating tissue regeneration, protein translation, and lipid oxidation mechanisms. Because IGF-1 serves as a principal mediator of growth hormone's anabolic actions, research models utilizing GHRH analogs frequently monitor collagen deposition, myoblast proliferation, and extracellular matrix remodeling.
In animal models of musculoskeletal injury, sustained IGF-1 elevation induced by CJC-1295 has been associated with accelerated satellite cell recruitment and enhanced muscular repair rates. Furthermore, investigators studying metabolic dysregulation utilize these compounds to examine adipocyte lipolysis and hepatic glucose output. To review additional research targets related to structural cellular maintenance, explore our guide on peptides for tissue repair.
Assuring high purity is critical when evaluating any CJC-1295 order for scientific use. Low-grade peptides containing truncated sequence sequences or residual TFA (trifluoroacetic acid) can cause cellular toxicity and invalidate experimental results. Reliable research suppliers must provide lot-specific Certificate of Analysis (COA) documents from ISO 17025 accredited analytical laboratories.
Purity verification should rely on Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring the target peptide peak accounts for >98% of total integrated area. Mass Spectrometry (MS) must be performed simultaneously to confirm exact molecular weight match (e.g., 3647.2 Da for CJC-1295 DAC free base). Additionally, quantitative Chromogenic LAL Endotoxin Testing must confirm endotoxin levels below 5 EU/mg to prevent inflammatory responses in delicate cell cultures or animal subjects. Academic and commercial institutions requiring bulk verification can set up direct procurement through our wholesale portal.
Lyophilized CJC-1295 powder should be stored in a freezer at -20°C upon receipt to maintain long-term stability. The dry cake is moisture-sensitive and should be allowed to warm to room temperature prior to reconstitution to minimize condensation inside the vial.
Reconstitution should be performed using sterile laboratory-grade Bacteriostatic Water (0.9% benzyl alcohol) or Sterile Water for Injection, depending on experimental requirements. Diluent should be introduced gently along the glass wall of the vial without aggressive vortexing, as turbulent shear forces can denature peptide secondary structures. Once reconstituted, solutions must be stored at 2°C to 8°C and utilized within 30 days to avoid hydrolytic cleavage.
When structuring endocrine research protocols, investigators often evaluate CJC-1295 alongside alternative secretagogues to determine the optimal kinetic profile for their experimental model. GHRH analogs like CJC-1295 DAC, Sermorelin, and Tesamorelin work directly through the GHRH receptor, whereas growth hormone secretagogue receptor (GHSR-1a) agonists like Ipamorelin act through the ghrelin pathway. The table and text below highlight the key functional differences across these standard research compounds.
While Sermorelin represents the native 1-29 sequence of GHRH with a rapid clearance profile (half-life ~10-12 minutes), Tesamorelin features a hexenoyl modification designed specifically to resist enzymatic cleavage while retaining a relatively short half-life. In contrast, CJC-1295 with DAC offers an extended half-life spanning several days. Combining GHRH analogs with selective GHSR agonists like Ipamorelin in preclinical models often results in synergistic GH secretion, generating higher peak releases than either compound administered individually.
Securing reliable laboratory reagents requires a systematic supplier evaluation framework. Researchers should avoid sources that lack clear analytical documentation or fail to provide lot-matched testing data. A robust vendor evaluation checklist includes verifying domestic synthesis standards, rapid logistics capabilities, and accessible analytical support.
PX1 Research maintains rigorous quality management protocols, manufacturing all peptides in GMP-compliant facilities within the United States. Every batch undergoes independent testing at an ISO 17025 laboratory, ensuring that your CJC-1295 order delivers uncompromised chemical purity, verified sequence integrity, and strict endotoxin compliance. Products are dispatched directly from our distribution hubs in California and Arizona with same-day shipping on weekday orders.
What is the key difference between CJC-1295 DAC and CJC-1295 No DAC?
The primary difference is the presence of the Drug Affinity Complex (DAC), which binds to serum albumin in vivo. This extends the biological half-life of CJC-1295 DAC to approximately 6–8 days, whereas CJC-1295 No DAC (Mod GRF 1-29) has a short half-life of roughly 30 minutes, producing rapid, transient GH spikes.
What analytical documentation should accompany a CJC-1295 order?
A valid CJC-1295 order should be accompanied by a lot-matched Certificate of Analysis (COA) that includes RP-HPLC chromatograms verifying >98% purity, Mass Spectrometry confirming correct molecular weight, and LAL assay results showing endotoxin levels below 5 EU/mg.
How should lyophilized CJC-1295 be stored in the lab?
Lyophilized CJC-1295 should be stored at -20°C in a dry environment away from light. Under these conditions, the powder remains stable for up to 24 months. Avoid repeated freeze-thaw cycles after reconstitution.
Which diluents are appropriate for reconstituting CJC-1295?
For multi-use laboratory bioassays over several days, Bacteriostatic Water (0.9% benzyl alcohol) is recommended to prevent microbial growth. For single-use acute cellular assays where preservatives might interfere, sterile 0.9% sodium chloride or sterile water for injection should be used.
Why is endotoxin testing vital for research peptides?
Bacterial endotoxins (lipopolysaccharides) can trigger acute inflammatory responses in animal models and alter signal transduction in cell cultures. Ensuring endotoxin levels are below 5 EU/mg prevents experimental artifacts caused by contamination.
Is CJC-1295 stable at room temperature during shipping?
Yes. Lyophilized CJC-1295 is chemically stable at ambient room temperatures for short periods during transit. Upon arrival at the laboratory facility, it should immediately be placed into cold storage at 2°C to 8°C (short term) or -20°C (long term).
Can CJC-1295 be co-administered with Ipamorelin in preclinical models?
Yes. In preclinical literature, GHRH analogs like CJC-1295 are frequently studied alongside GHSR agonists like Ipamorelin to investigate signal amplification and synergistic growth hormone secretion.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.